The Reduced Insulinotropic Effect of a Continuous Infusion Relative to a Bolus Injection of GIP
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
In patients with type 2 diabetes, the incretin hormone glucose-dependent insulinotropic
polypeptide (GIP) has lost its insulinotropic activity, but more so after continuous versus
bolus administration. The design was a two-way crossover design comparing repeated bolus
injection and continuous infusion of GIP under hyperglycaemic clamp conditions. Patients were
age- gender- and weight-matched with type 2 diabetes, first degree relatives of such
patients, and healthy subjects. Investigators performed a:
1. Oral glucose challenge;
2. hyperglycemic clamp (8.5 mmol/l) with two repeated GIP bolus administrations (50 pmol/kg
body weight at 30 and 120 min); and
3. hyperglycemic clamp with continuous administration of GIP (2 pmol.kg-1.min-1 from 30-180
min).
To answer the question, whether rapid tachyphylaxis occurs with regard to the insulinotropic
action of GIP, investigators studied type 2-diabetic patients, their first-degree relatives,
and healthy controls under hyperglycaemic clamp conditions with two GIP bolus injections 90
min apart, and compared this to a continued intravenous infusion of GIP.